SCHEMBL286768

SCHEMBL286768

COc1cc(CCO)cc2c1C(=O)OC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
GAA P10253 3/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
LMNA P02545 2/20 0.47
CYP3A4 P08684 2/20 0.46
PDE5A O76074 1/20 0.43
PDE4A P27815 1/20 0.43
PDE1A P54750 1/20 0.43
PDE1B Q01064 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
PDE3B Q13370 1/20 0.43
PDE1C Q14123 1/20 0.43
PDE3A Q14432 1/20 0.43
IMPDH2 P12268 2/20 0.43
IMPDH1 P20839 1/20 0.43
KCNJ1 P48048 1/20 0.41
KCNH2 Q12809 1/20 0.41
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286469 0.81 IMPDH2 (0.48) KDM4EGAASMN1; SMN2LMNACYP3A4
SCHEMBL286747 0.78 CYP3A4 (0.51) KDM4EGAASMN1; SMN2LMNACYP3A4
SCHEMBL29434781 0.74 KDM4E (0.71) KDM4EGAASMN1; SMN2LMNACYP3A4
SCHEMBL2060122 0.74 KDM4E (0.71) KDM4EGAASMN1; SMN2LMNACYP3A4
SCHEMBL20231727 0.73 CYP3A4 (0.53) KDM4EGAASMN1; SMN2LMNACYP3A4
SCHEMBL31496832 0.73 CYP3A4 (0.53) KDM4EGAASMN1; SMN2LMNACYP3A4
SCHEMBL286593 0.70 KDM4E (0.49) KDM4EGAASMN1; SMN2LMNACYP3A4
SCHEMBL286654 0.69 KCNJ1 (0.66) GAALMNAKCNJ1KCNH2ALDH1A1
SCHEMBL286641 0.69 KDM4E (0.48) KDM4EGAASMN1; SMN2LMNACYP3A4
SCHEMBL15240817 0.68 TNKS2 (0.67) KDM4EGAALMNATNKS2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427444-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2015-12-16 EP disclosed
US-9018211-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2015-04-28 US disclosed
US-20140142115-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2014-05-22 US disclosed
US-8673920-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2014-03-18 US disclosed
EP-2427444-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL Merck Sharp & Dohme Corp. (US) 2012-03-14 EP disclosed
WO-2010129379-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2010-11-11 WO disclosed
US-20100286123-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142115-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, KCNJ2 KDM4E 1977/4885GAA 4056/4885SMN1; SMN2 1651/4885
US-20100286123-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, KCNJ2 KDM4E 1977/4885GAA 4056/4885SMN1; SMN2 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.